Gan & Lee(SH:603087)2024-07-08 08:41Financial Performance Forecast - The company expects a net profit attributable to shareholders for the first half of 2024 to be between 290 million and 330 million yuan, representing an increase of 155.84 million to 195.84 million yuan compared to the same period last year, a year-on-year increase of 116.17% to 145.98% [2]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 110 million and 140 million yuan, an increase of 7.61% to 36.96% compared to the same period last year [3]. - The total profit for the same period last year was 159.69 million yuan, with a net profit attributable to shareholders of 134.16 million yuan [4]. Revenue Growth - The company's revenue for the first half of 2024 is expected to show steady growth, primarily due to stable sales growth of domestic insulin preparations [5]. Impact of Non-Recurring Items - Non-recurring gains and losses significantly impacted net profit, mainly due to increased fair value changes and investment income from trading financial assets compared to the previous year [5]. Forecast Reliability - The company does not foresee any major uncertainties that could affect the accuracy of this performance forecast [6]. - The forecast data is preliminary and subject to final confirmation in the official 2024 semi-annual report [6].